Vicore Q3/2019 results reflected a smaller net loss than we had anticipated, due largely to lower R&D and other external expenses. Although we expect R&D costs to increase in Q4 vs. Q3 as lead asset VP01 enters two Phase IIa trials, we have lowered our FY2019E forecasts for operating expenses and hence net loss. We have also updated our model for the recent SEK125m directed share issue, which on our estimates extends the cash runway into 2021E. While this has also lowered our valuatio
14 Nov 2019
Two Phase IIa trials to start by YE2019E
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Two Phase IIa trials to start by YE2019E
Vicore Pharma Holding AB (6Y4:FRA) | 0 0 0.0%
- Published:
14 Nov 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
12
Vicore Q3/2019 results reflected a smaller net loss than we had anticipated, due largely to lower R&D and other external expenses. Although we expect R&D costs to increase in Q4 vs. Q3 as lead asset VP01 enters two Phase IIa trials, we have lowered our FY2019E forecasts for operating expenses and hence net loss. We have also updated our model for the recent SEK125m directed share issue, which on our estimates extends the cash runway into 2021E. While this has also lowered our valuatio